^
Association details:
| Biomarker: | KIT exon 14 mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial
Published date:
01/20/2022
Excerpt:
In archived tumor samples, 67% (68/102) had a KIT mutation; 61% (62/102) had primary KIT mutations (exons 9 and 11) and 12% (12/102) had secondary mutations (exons 13, 14, 17, and 18)….Regorafenib showed PFS benefit across all primary and secondary KIT mutational subgroups examined....These data support the results of the GRID trial, and suggest that patients may benefit from regorafenib in the presence of KIT mutations...
DOI:
https://doi.org/10.1007/s10120-021-01274-6
